Cargando…

Profile of pacritinib and its potential in the treatment of hematologic disorders

Pacritinib (previously known as SB-1518) is an innovative selective inhibitor of Janus kinase 2 and FMS-related tyrosine kinase 3 providing potential in the treatment of hematological malignancies such as myeloproliferative neoplasias, acute myeloid leukemia, and various lymphomas. Pacritinib has po...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatzimichael, Eleftheria, Tsolas, Evangelos, Briasoulis, Evangelos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145824/ https://www.ncbi.nlm.nih.gov/pubmed/25170285 http://dx.doi.org/10.2147/JBM.S51253

Ejemplares similares

Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches
por: Tzakos, Andreas G., et al.
Publicado: (2011)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

Hyponatremia in Patients with Hematologic Diseases
por: Koumpis, Epameinondas, et al.
Publicado: (2020)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2023)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures
por: Singer, Jack W., et al.
Publicado: (2019)

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
por: Petrova, Tsvetana, et al.
Publicado: (2023)

Hematopoietic stem cell transplantation
por: Hatzimichael, Eleftheria, et al.
Publicado: (2010)

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011)

P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS
por: Masarova, Lucia, et al.
Publicado: (2023)

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
por: Dranitsaris, George, et al.
Publicado: (2012)

Cancer Epigenetics: New Therapies and New Challenges
por: Hatzimichael, Eleftheria, et al.
Publicado: (2013)

Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Barakos, Georgios Petros, et al.
Publicado: (2022)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

The Role of Non-Coding RNAs in Myelodysplastic Neoplasms
por: Georgoulis, Vasileios, et al.
Publicado: (2023)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
por: Hatzimichael, Eleftheria, et al.
Publicado: (2022)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
por: Al-Fayoumi, Suliman, et al.
Publicado: (2018)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
por: Ghezzi, Chiara, et al.
Publicado: (2023)

P1059: COMPARATIVE EFFICACY OF FEDRATINIB AND PACRITINIB FOR THE TREATMENT OF MYELOFIBROSIS IN PATIENTS WITH LOW PLATELET COUNTS: A SIMULATED TREATMENT COMPARISON STUDY
por: Tremblay, G., et al.
Publicado: (2022)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Novel Therapeutic Advances in β-Thalassemia
por: Makis, Alexandros, et al.
Publicado: (2021)

PPARγ: The Portrait of a Target Ally to Cancer Chemopreventive Agents
por: Sainis, Ioannis, et al.
Publicado: (2008)

Profile of agomelatine and its potential in the treatment of generalized anxiety disorder
por: Levitan, Michelle Nigri, et al.
Publicado: (2015)

Alterations of MicroRNAs in Solid Cancers and Their Prognostic Value
por: Chira, Panagiota, et al.
Publicado: (2010)

Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
por: Froudarakis, Marios E, et al.
Publicado: (2010)

Food Applications and Potential Health Benefits of Pomegranate and its Derivatives
por: Kandylis, Panagiotis, et al.
Publicado: (2020)

Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial
por: Cafardi, John, et al.
Publicado: (2022)

Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
por: Georgoulis, Vasileios, et al.
Publicado: (2023)

Cyanobacterial Cyclopeptides as Lead Compounds to Novel Targeted Cancer Drugs
por: Sainis, Ioannis, et al.
Publicado: (2010)

Notch signaling: its roles and therapeutic potential in hematological malignancies
por: Gu, Yisu, et al.
Publicado: (2016)

Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival
por: Katodritou, Eirini, et al.
Publicado: (2018)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sa4v7gk45rl1un4t76vvtrt4kj